CA2985325C - Cyclic compounds for inhibition of toll-like receptor 4 - Google Patents

Cyclic compounds for inhibition of toll-like receptor 4 Download PDF

Info

Publication number
CA2985325C
CA2985325C CA2985325A CA2985325A CA2985325C CA 2985325 C CA2985325 C CA 2985325C CA 2985325 A CA2985325 A CA 2985325A CA 2985325 A CA2985325 A CA 2985325A CA 2985325 C CA2985325 C CA 2985325C
Authority
CA
Canada
Prior art keywords
group
compound
mixture
ethyl
ene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2985325A
Other languages
English (en)
French (fr)
Other versions
CA2985325A1 (en
Inventor
Toshitake Kobayashi
Morihisa Saitoh
Yasufumi Wada
Hiroshi Nara
Nobuyuki Negoro
Taisuke KATOH
Masashi Yamasaki
Takahiro Tanaka
Naomi Kitamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2985325A1 publication Critical patent/CA2985325A1/en
Application granted granted Critical
Publication of CA2985325C publication Critical patent/CA2985325C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/12Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2985325A 2015-05-08 2016-05-06 Cyclic compounds for inhibition of toll-like receptor 4 Active CA2985325C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-095817 2015-05-08
JP2015095817 2015-05-08
PCT/JP2016/064204 WO2016182036A1 (en) 2015-05-08 2016-05-06 Cyclic compounds

Publications (2)

Publication Number Publication Date
CA2985325A1 CA2985325A1 (en) 2016-11-17
CA2985325C true CA2985325C (en) 2023-09-26

Family

ID=56132991

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2985325A Active CA2985325C (en) 2015-05-08 2016-05-06 Cyclic compounds for inhibition of toll-like receptor 4

Country Status (11)

Country Link
US (3) US9611244B2 (https=)
EP (1) EP3294706B1 (https=)
JP (1) JP6718884B2 (https=)
CN (1) CN107835800B (https=)
AR (1) AR104539A1 (https=)
CA (1) CA2985325C (https=)
EA (1) EA033083B1 (https=)
ES (1) ES2772703T3 (https=)
TW (1) TW201704206A (https=)
UY (1) UY36675A (https=)
WO (1) WO2016182036A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107835800B (zh) * 2015-05-08 2019-11-26 武田药品工业株式会社 环状化合物
WO2018047888A1 (ja) 2016-09-09 2018-03-15 武田薬品工業株式会社 環状化合物
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2214398C2 (ru) 1998-03-09 2003-10-20 Такеда Кемикал Индастриз, Лтд. Производное циклоалкена, способ его получения (варианты), фармацевтическая композиция, способ ингибирования, способ профилактики или лечения
DE60045033D1 (de) 1999-08-06 2010-11-11 Takeda Pharmaceutical Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung
JP2004002370A (ja) * 2002-04-08 2004-01-08 Takeda Chem Ind Ltd 重症セプシス予防治療剤
US20060058288A1 (en) 2002-04-08 2006-03-16 Masayuki Ii Severe sepsis preventive therapeutic agent
KR101327610B1 (ko) 2005-09-14 2013-11-12 다이이찌 산쿄 가부시키가이샤 치환 시클로알켄 유도체
JP2008260760A (ja) 2007-03-12 2008-10-30 Daiichi Sankyo Co Ltd 置換シクロアルケン誘導体を含有する医薬組成物
US20100137787A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
TWI481401B (zh) 2010-01-27 2015-04-21 Takeda Pharmaceutical 藥劑
CN107835800B (zh) * 2015-05-08 2019-11-26 武田药品工业株式会社 环状化合物

Also Published As

Publication number Publication date
CN107835800B (zh) 2019-11-26
AR104539A1 (es) 2017-07-26
EA201792469A1 (ru) 2018-06-29
EP3294706A1 (en) 2018-03-21
TW201704206A (zh) 2017-02-01
CN107835800A (zh) 2018-03-23
US20160326102A1 (en) 2016-11-10
CA2985325A1 (en) 2016-11-17
JP6718884B2 (ja) 2020-07-08
US20170066737A1 (en) 2017-03-09
WO2016182036A1 (en) 2016-11-17
BR112017023818A2 (pt) 2018-07-31
UY36675A (es) 2016-12-30
US9828357B2 (en) 2017-11-28
EA033083B1 (ru) 2019-08-30
JP2018516875A (ja) 2018-06-28
US9533966B2 (en) 2017-01-03
US20160326133A1 (en) 2016-11-10
ES2772703T3 (es) 2020-07-08
US9611244B2 (en) 2017-04-04
EP3294706B1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
JP6671456B2 (ja) 複素環化合物
AU2015285142B2 (en) Heterocyclic compounds and their use as Retinoid-related orphan receptor (ROR) gamma-T inhibitors
US10406146B2 (en) Heterocyclic compound
WO2015068856A1 (en) Pyrazole for the treatment autoimmune disorders
CA2985325C (en) Cyclic compounds for inhibition of toll-like receptor 4
WO2015146929A1 (ja) 複素環化合物
CN109923101B (zh) 环状化合物
EP3296296A1 (en) Cyclic compound
BR112017023818B1 (pt) Composto, e, medicamento

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210331

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250424

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421